Technical Analysis for CTIC - Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 1.28 0.79% 0.01
CTIC closed up 0.79 percent on Wednesday, January 16, 2019, on 39 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical CTIC trend table...

Date Alert Name Type % Chg
Jan 16 NR7 Range Contraction 0.00%
Jan 16 Wide Bands Range Expansion 0.00%
Jan 15 New Downtrend Bearish 0.79%
Jan 15 Hammer Candlestick Bullish 0.79%
Jan 15 Wide Bands Range Expansion 0.79%
Jan 15 Overbought Stochastic Strength 0.79%
Jan 14 New Uptrend Bullish -0.78%
Jan 14 Weak + Overbought Other -0.78%
Jan 14 Wide Bands Range Expansion -0.78%
Jan 14 Overbought Stochastic Strength -0.78%

Older signals for CTIC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
Is CTIC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.36
52 Week Low 0.6
Average Volume 297,199
200-Day Moving Average 2.7467
50-Day Moving Average 1.416
20-Day Moving Average 1.107
10-Day Moving Average 1.274
Average True Range 0.1356
ADX 32.34
+DI 23.6884
-DI 26.8121
Chandelier Exit (Long, 3 ATRs ) 1.0732
Chandelier Exit (Short, 3 ATRs ) 1.0068
Upper Bollinger Band 1.5396
Lower Bollinger Band 0.6744
Percent B (%b) 0.7
BandWidth 78.157182
MACD Line -0.0204
MACD Signal Line -0.0711
MACD Histogram 0.0507
Fundamentals Value
Market Cap 40.61 Million
Num Shares 31.7 Million
EPS -1.88
Price-to-Earnings (P/E) Ratio -0.68
Price-to-Sales 2.78
Price-to-Book 2.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.40
Resistance 3 (R3) 1.40 1.37 1.38
Resistance 2 (R2) 1.37 1.34 1.37 1.37
Resistance 1 (R1) 1.32 1.32 1.35 1.32 1.37
Pivot Point 1.29 1.29 1.30 1.29 1.29
Support 1 (S1) 1.24 1.26 1.27 1.24 1.19
Support 2 (S2) 1.21 1.24 1.21 1.19
Support 3 (S3) 1.16 1.21 1.18
Support 4 (S4) 1.16